Advanced Search

Journal of Traditional Chinese Medicine >

2025 , Vol. 45 >Issue 5: 1009 - 1018

DOI: https://doi.org/10.19852/j.cnki.jtcm.20250327.001

Original Articles

Liquid chromatography-mass spectrometry-based metabolomics study of the protective mechanism of Shenji Guben decoction (参吉固本方) on chronic obstructive pulmonary disease

  • Tingyu PAN ,
  • Jing YAO ,
  • Yue GE ,
  • Shuang YANG ,
  • Zikai SUN ,
  • Yu WEI ,
  • Jieyu WU ,
  • Yong XU ,
  • Xianmei ZHOU ,
  • Hailang HE
Expand
  • 1 Department of Pulmonary and Critical Care Medicine, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210018, China
    2 Department of Pulmonary Medicine, Suzhou Hospital of Integrated Traditional Chinese and Western Medicine, Suzhou 215101, China
    3 School of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China
PAN Tingyu and YAO Jing are co-first authors and contributed equally to this work

Received date: 2024-09-11

  Accepted date: 2024-12-22

  Online published: 2025-03-27

Supported by

Traditional Chinese Medicine Science and Technology Development Plan of Jiangsu Province(MS2021013);Traditional Chinese Medicine Science and Technology Development Plan of Jiangsu Province(ZD202215);Exploring the Efficacy and Mechanism of Professor Cao Shihong's Shenji Guben Decoction in Treating Chronic Obstructive Pulmonary Disease Based on Metabolomics, a Real-World Cohort Study on Traditional Chinese Medicine for the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease;Intra-hospital Fund of Jiangsu Provincial Hospital of Traditional Chinese Medicine Development(Y2021ZR11);Investigating the Mechanism of Shenji Guben Decoction in Treating Chronic Obstructive Pulmonary Disease Based on Metabolomics

Fold

Abstract

OBJECTIVE: To investigate the mechanisms of the effect of Shenji Guben (SJGB) decoction (参吉固本方) on chronic obstructive pulmonary disease (COPD).

METHODS: A murine model of COPD was established through lipopolysaccharide (LPS) nasal drops and passive smoke exposure, followed by evaluation of SJGB decoction efficacy via lung function tests and histological analysis. Non-targeted liquid chromatography-mass spectrometry (LC-MS)-based metabolomics was used to explore the mechanisms of SJGB decoction in COPD.

RESULTS: We found that the SJGB decoction effectively reduced inflammatory cell infiltration in the airways and lungs, and improved lung function in the COPD model mice. LC-MS-based metabolomics identified 86 biomarkers in COPD models. Compared to the model group, SJGB decoction significantly altered 34 metabolites. Prostaglandin E2 and DL-Citrulline were highlighted as two representative differential metabolites. MetaboAnalyst 5.0 highlighted glycerophospholipid and riboflavin metabolisms as key pathways affected by SJGB decoction.

CONCLUSION: This study evaluated the protective effect of SJGB decoction against COPD and provided insights into its potential mechanisms in COPD treatment.

Key words： pulmonary disease, chronic obstructive; metabolomics; glycerophospholipids; dinoprostone; Shenji Guben decoction

Cite this article

Tingyu PAN , Jing YAO , Yue GE , Shuang YANG , Zikai SUN , Yu WEI , Jieyu WU , Yong XU , Xianmei ZHOU , Hailang HE . Liquid chromatography-mass spectrometry-based metabolomics study of the protective mechanism of Shenji Guben decoction (参吉固本方) on chronic obstructive pulmonary disease[J]. Journal of Traditional Chinese Medicine, 2025 , 45(5) : 1009 -1018 . DOI: 10.19852/j.cnki.jtcm.20250327.001

References

1. Celli B, Fabbri L, Criner G, et al. Definition and nomenclature of chronic obstructive pulmonary disease: time for its revision. Am J Respir Crit Care Med 2022; 206: 1317-25.
2. Collaborators GBDCRD. Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet Respir Med 2020; 8: 585-96.
3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3: e442.
4. Sin DD, Doiron D, Agusti A, et al. Air pollution and COPD: GOLD 2023 committee report. Eur Respir J 2023; 61: 2202469.
5. Kahnert K, Jorres RA, Behr J, et al. The diagnosis and treatment of COPD and its comorbidities. Dtsch Arztebl Int 2023; 120: 434-44.
6. Cao X, Wang Y, Chen Y, et al. Advances in Traditional Chinese Medicine for the treatment of chronic obstructive pulmonary disease. J Ethnopharmacol 2023; 307: 116229.
7. Sun Z. Jinling famous doctor CAO Shi-hong's experience in treating pulmonary diseases. Zhong Hua Zhong Yi Yao Za Zhi 2017; 32: 190-3.
8. Sun Z, Cao A, Xu L, et al. The curative effect on patients suffered from COPD in catabasis with the method of tonifying kidney biopsy and solidifying fundemental. Shi Zhen Guo Yi Guo Yao 2007; 12: 2980-2.
9. Pan T, Han D, Xu Y, et al. LC-MS based metabolomics study of the effects of EGCG on A 549 cells. Front Pharmacol 2021; 12: 732716.
10. Nambiar S, Bong How S, Gummer J, et al. Metabolomics in chronic lung diseases. Respirology 2020; 25: 139-48.
11. Naz S, Garcia A, Barbas C. Multiplatform analytical methodology for metabolic fingerprinting of lung tissue. Anal Chem 2013; 85: 10941-8.
12. Ran N, Pang Z, Gu Y, et al. An updated overview of metabolomic profile changes in chronic obstructive pulmonary disease. Metabolites 2019; 9: 111.
13. Xu LT, Wang T, Han QT, et al. Integrated network pharmacology and pharmacological investigations to explore the potential mechanism of Ding-Chuan-Tang against chronic obstructive pulmonary disease. J Ethnopharmacol 2024; 327: 117983.
14. Yang Y, Di T, Zhang Z, et al. Dynamic evolution of emphysema and airway remodeling in two mouse models of COPD. BMC Pulm Med 2021; 21: 134.
15. Huang X, Guan W, Xiang B, et al. MUC5B regulates goblet cell differentiation and reduces inflammation in a murine COPD model. Respir Res 2022; 23: 11.
16. Ren H, Wu W, Chen J, et al. Integrated serum metabolomics and network pharmacology analysis on the bioactive metabolites and mechanism exploration of Bufei huoxue capsule on chronic obstructive pulmonary disease rats. J Ethnopharmacol 2024; 324: 117816.
17. Nici L, Mammen MJ, Charbek E, et al. Pharmacologic management of chronic obstructive pulmonary disease. An official American thoracic society clinical practice guideline. Am J Respir Crit Care Med 2020; 201: e56-69.
18. He H, Shi X, Lawrence A, et al. 2,2',4,4'-tetrabromodiphenyl ether (BDE-47) induces wide metabolic changes including attenuated mitochondrial function and enhanced glycolysis in PC12 cells. Ecotoxicol Environ Saf 2020; 201: 110849.
19. Zampieri M, Sekar K, Zamboni N, et al. Frontiers of high-throughput metabolomics. Curr Opin Chem Biol 2017; 36: 15-23.
20. Li J, Liu X, Shi Y, et al. Differentiation in TCM patterns of chronic obstructive pulmonary disease by comprehensive metabolomic and lipidomic characterization. Front Immunol 2023; 14: 1208480.
21. Agudelo CW, Samaha G, Garcia-Arcos I. Alveolar lipids in pulmonary disease. A review. Lipids Health Dis 2020; 19: 122.
22. Gariballa S, Forster S, Powers H. Riboflavin status in acutely ill patients and response to dietary supplements. JPEN J Parenter Enteral Nutr 2009; 33: 656-61.
23. Yang IA, Jenkins CR, Salvi SS. Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment. Lancet Respir Med 2022; 10: 497-511.
24. Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol 2009; 4: 435-59.
25. Mao Y, Shi D, Li G, et al. Citrulline depletion by ASS1 is required for proinflammatory macrophage activation and immune responses. Mol Cell 2022; 82: 527-41.
26. Bahadoran Z, Mirmiran P, Kashfi K, et al. Endogenous flux of nitric oxide: citrulline is preferred to arginine. Acta Physiol (Oxf) 2021; 231: e13572.
27. Phillips DB, Brotto AR, Ross BA, et al. Inhaled nitric oxide improves ventilatory efficiency and exercise capacity in patients with mild COPD: a randomized-control cross-over trial. J Physiol 2021; 599: 1665-83.
28. Yatera K, Mukae H. Nitric oxide/nitric oxide synthase in the pathogenesis of pulmonary emphysema. Respir Investig 2022; 60: 443-5.
Options
Outlines

/

〈 〉